NCT03836001已完成2 期
A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 1
- 主要终点
- Number of Patients Who Achieve at Least a 3-point Reduction in AI-NRS.
研究概览
简要总结
To determine if Serlopitant (when taken by mouth) is safe and works on itch in patients aged 13 and above with EB.
详细描述
The investigator will determine whether more patients taking serlopitant 5 mg daily as compared to placebo can achieve at least a 3-point reduction in the 24-hour Average Itch Numeric Rating Scale (NRS) following two months of treatment.
Secondary objectives include;
- comparative weekly change in daily worst itch NRS,
- comparative weekly change in daily average itch NRS,
- the proportion of patients who achieve at least 30% or 50% reduction in Average Itch NRS at month 2,
- proportion of patients achieving 2-point and 4-point reductions in Average Itch NRS at month 2,
- Patient Global Impression of Change (PGIC) at month 2, the change in participant static assessment of itch at month 2, and
- assessment of the safety of serlopitant in adolescents (≥13 y.o.) and adults with epidermolysis bullosa-related itch.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
This is a double-blind study.
入排标准
- 年龄范围
- 13 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males or females who are at least 13 years of age.
- •Willing and able to understand and sign informed assent/consent. Adolescents will need a parent or guardian willing and able to give consent.
- •Clinical diagnosis of epidermolysis bullosa (dystrophic, junctional or simplex).
- •History of chronic pruritus of at least 6 weeks in duration
- •On the Screening Visit or Screening phone call, patients must have an NRS pruritus score of at least 5 on average itch score in the past 24 hours
- •Female subjects must be of non-childbearing potential (ie, post-menopausal for at least 1 year, had a hysterectomy, or had a tubal ligation) or, if of childbearing potential, must have a confirmed negative urine pregnancy test prior to study treatment and be willing to use effective contraception for the duration of the trial. Effective contraception is defined as follows: oral/implant/injectable/ transdermal contraceptives, intrauterine device, condom with spermicide, or diaphragm with spermicide. Abstinence or partner's vasectomy is acceptable if the female agrees to use effective contraception if she decides to discontinue abstinence or to have sexual intercourse with a non-vasectomized partner.
- •Judged to be in good health based upon the results of a physical examination, medical history, and safety laboratory tests.
排除标准
- •Have any medical condition or disability that would interfere with the assessment of safety or efficacy in this trial or would compromise the ability of the subject to travel to Stanford or to undergo study procedures or to give informed consent.
- •Have a history of sensitivity to any components of the study material.
- •Are females of childbearing potential who are unwilling to use adequate contraception or who are breast feeding.
- •Have any chronic or acute medical condition that, in the opinion of the investigator, might interfere with the study results or place the subject at undue risk.
- •Have chronic renal disease, i.e., serum creatinine greater than 2 times the upper limit of normal.
- •Have chronic liver disease. Subjects with hepatitis B and C who have normal liver function may be enrolled.
- •Have a current malignancy (such as Hodgkin's lymphoma, B or T cell lymphoma, or myeloma) or blood cell dyscrasia (e.g., polycythemia or myelofibrosis) that would lead to systemic chronic pruritus.
- •Have a history of thyroid cancer, thyroid nodules, inadequately treated thyroid disease, or abnormal TSH or free T4 at screening.
- •Have a history of abnormalities in adrenal or pituitary function (pituitary adenoma, adrenal insufficiency, or adrenal nodule).
- •Screening cortisol level < 3 mcg/dL
- •Unevaluated abnormalities in cortisol, ACTH, or prolactin.
- •Have pruritus of psychogenic etiology (delusions of parasitosis, obsessive compulsive disorder and major depression) or neuropathic etiology (due to shingles, spinal cord injury or with neurologic deficit).
- •Have pruritus due to urticaria, drug allergy, or infection (such as pityriasis rosacea or tinea or active human immunodeficiency virus [HIV]). Note: Subjects with HIV who have undetectable viral load, and stable retro-viral therapy may enroll.
- •Have taken investigational medications within 30 days prior to Screening.
- •Are unwilling to discontinue specific medications that, in the view of the investigator may have significant interactions with the trial drug, for at least two weeks prior to initiation of study and throughout the study period (this includes miconazole, delavirdine, conivaptan, Clarithromycin, telithromycin, nefazodone, itraconazole, ketoconazole, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir).
- •Are unable or unwilling to maintain their current anti-itch and opioid-based pain medications at a stable dosage through the course of the two months of active treatment (including but not limited to opioid pain medications, antihistamines, and gabapentin)
- •Started or changed medications, creams, or emollients including over-the-counter (OTC) preparations or bath oil treatment specifically for relief of pruritus within 30 days prior to Screening.
- •Within in the past 12 months, have expressed suicidal ideation with some intent to act.
- •Have any social or medical condition (e.g. alcoholism, drug dependency, psychotic state) that, in the investigator's opinion, might interfere with the subject's ability to comply with the requirements of the protocol.
研究组 & 干预措施
Placebo Oral Tablet
Placebo Comparator
Participants will undergo two months of dosing with a placebo (inactive drug or sugar pill), followed by one month of washout. After the washout period, all participants were invited to participate in an open-label extension study with serlopitant 5 mg daily. The duration of the open-label extension study was either 12 months (for those who enrolled before May 2020) or 3 months (for those who registered after May 2020) due to drug availability.
干预措施: Placebo Oral Tablet (Drug)
Serlopitant Tablet
Active Comparator
Participants will undergo two months of Serlopitant 5mg daily per oral, followed by one month of washout. After the washout period, all participants were invited to participate in an open-label extension study with serlopitant 5 mg daily. The duration of the open-label extension study was either 12 months (for those who enrolled before May 2020) or 3 months (for those who registered after May 2020) due to drug availability.
干预措施: Serlopitant Tablet (Drug)
结局指标
主要结局
Number of Patients Who Achieve at Least a 3-point Reduction in AI-NRS.
时间窗: baseline and after two months of treatment
Participants will be asked to complete a daily itch diary with their average itch numeric rating scale (AI-NRS) over the past 24 hours. Score range: 0 to 10, higher scores mean more itching.
次要结局
- Number of Patients Who Achieve at Least a 4-point Reduction in AI-NRS.(baseline and after two months of treatment)
- Patient Global Impression of Change (PGIC)(month 2)
- Change in Static Participant Assessment of Itch(month 2)
- Number of Patients Who Achieve at Least a 50% Reduction in AI-NRS.(baseline and after two months of treatment)
- Number of Patients Who Achieve at Least a 2-point Reduction in AI-NRS.(baseline and after two months of treatment)
- Weekly AI-NRS(baseline and week 1, 2, 3, 4, 5, 6, 7, and 8)
- Number of Patients Who Achieve at Least a 30% Reduction in AI-NRS.(baseline and after two months of treatment)
- Weekly Worst Itch NRS(baseline and week 1, 2, 3, 4, 5, 6, 7, and 8)
研究者
Albert Chiou
Assistant Professor of Dermatology.
Stanford University
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Study of oral neurokinin-1 antagonist, aprepitant for the prevention of nausea and vomiting in patients receiving chemotherapy with irinotecan alone or combination of irinotecan plus cisplatin for unresectable gastric cancergastric cancerJPRN-UMIN000004021Division of Upper Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine80
招募中
2 期
Efficacy of NK1 receptor antagonist (aprepitant) in the cancer chemotherapies for hematologic malignancies.hematologic malignanciesJPRN-UMIN000006690Kagoshima University Hospital, division of Hematology and Immunology40
进行中（未招募）
1 期
PHARMACOKINETICS OF ORAL SPIRONOLACTONE IN CHILDREN UP TO 2 YEARS OF AGEEUCTR2013-001189-40-EEniversity of Tartu27
招募中
不适用
Effect of oral neurokinin-1 antagonist, aprepitant for chemotherapy-induced nausea and vomiting in patients with gynecologic cancer receiving carboplatin/paclitaxel chemotherapy.JPRN-UMIN000005317Department of gynecology, Fukuoka University Hospital60
已完成
不适用
Study of oral neurokinin-1 antagonist, aprepitant for prevention of nausea and emesis in patients receiving chemotherapy including cisplatin for gastric cancer.gastric cancerJPRN-UMIN000004175Division of gastroenterologic surgery, Kanazawa University55